SCM
SION

Superstring Capital Management’s Sionna Therapeutics SION Stock Holding History

Superstring Capital Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
63,156
-77,868
-55% -$3.11M 1.75% 21
2026
Q1 		$5.65M Sell
141,024
-39,569
-22% -$1.51M 4.04% 10
2025
Q4 		$7.43M Buy
+180,593
New +$6.85M 3.98% 6

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Superstring Capital Management's SION Position: Q2 2026 in Review

Superstring Capital Management reduced its Sionna Therapeutics (SION) stake by 55% in Q2 2026, selling an estimated $3.11M and leaving 63,156 shares worth $2.78M. The position accounts for 1.75% of the portfolio, ranked #21.

Superstring Capital Management first reported a position in SION in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.43M in Q4 2025. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Superstring Capital Management held 63,156 shares of Sionna Therapeutics worth $2.78M as of Q2 2026.
  • Superstring Capital Management sold 77,868 Sionna Therapeutics shares in Q2 2026, an estimated $3.11M.
  • Sionna Therapeutics made up 1.75% of Superstring Capital Management's portfolio in Q2 2026, its #21 holding.
  • Superstring Capital Management first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Superstring Capital Management's Sionna Therapeutics position peaked at $7.43M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.